KeyCorp lifts Certara stock target to USD 12.00

Published on 10/17/2026 at 22:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Certara reports on November 5, 2026. Certara stock last stood at USD 9.37 on October 16, 2026 at 4:00 p.m. ET, down 3.00 percent on Nasdaq.

Analyst target and reporting date

KeyCorp raised its Certara target to USD 12.00 on October 16, 2026.
Certara is scheduled to report third-quarter results on November 5, 2026.
Certara stock last stood at USD 9.37 on October 16, 2026 at 4:00 p.m. ET, down 3.00 percent on Nasdaq.
Certara had a market capitalization of USD 1.4 billion and a P/E ratio of minus 21.13 on October 16, 2026.

CERT, US15687V1098, Illustration mit AI erstellt.

KeyCorp raised its price target for Certara from USD 9.00 to USD 12.00 and maintained an Overweight rating in a report dated October 16, 2026, according to MarketBeat. The new target is 28.81 percent above the Nasdaq price of USD 9.37, calculated from the two cited values. Certara stock last stood at USD 9.37 on October 16, 2026 at 4:00 p.m. ET, down 3.00 percent from the prior Nasdaq close.

November 5 results date

Certara is estimated to report third-quarter 2026 results before the market opens on November 5, 2026, with a conference call scheduled for 5:00 p.m. ET, according to MarketBeat. The same calendar page lists consensus revenue of USD 92.31 million and consensus earnings per share of USD 0.0869 for the quarter.

Stock range USD 4.45 to USD 12.94

The stock's 52-week range was USD 4.45 to USD 12.94 on October 16, 2026. The latest price was 27.58 percent below the high and 110.56 percent above the low, calculated from the Nasdaq values. The stock also closed below its 50-day moving average of USD 8.52 in the MarketBeat report, while its 200-day moving average stood at USD 6.95.

Valuation at minus 21.13 times earnings

Certara's market capitalization was USD 1.4 billion and its P/E ratio was minus 21.13 on October 16, 2026. The company describes its business as software and technology-enabled services for drug development, including biosimulation, clinical intelligence and regulatory science. Its investor-relations page says Certara serves more than 2,600 biopharmaceutical companies, academic institutions and regulatory agencies, according to Certara.

Comparison with peers

CERT (Nasdaq, USD): minus 3.00 percent, P/E minus 21.13, market capitalization USD 1.4 billion.

Medpace (Nasdaq, USD): minus 1.61 percent, P/E 36.23, market capitalization USD 17.3 billion.

ICON (Nasdaq, USD): minus 2.83 percent, P/E 39.95, market capitalization USD 13.1 billion.

Price and investor calendar

Certara remains smaller than both selected clinical-research peers by market capitalization, while its negative P/E reflects the latest loss-making earnings base. The next scheduled reporting date is November 5, 2026, before the Nasdaq session.

The last available Nasdaq price was USD 9.37 on October 16, 2026 at 4:00 p.m. ET, down 3.00 percent versus the prior Nasdaq close.